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removal of excess cholesterol from macrophages in the ar-
terial wall and subsequent delivery to the liver for biliary 
excretion. Interest in the enzyme increased even further 
when in 1967 the fi rst family with three sisters with familial 
LCAT defi ciency was described ( 4 ). To date, approxi-
mately 60 isolated cases and 70 small families with partial 
or complete LCAT defi ciency have been described with 86 
different molecular defects in the LCAT gene ( 5 ) (http://
www.hgmd.org). In addition, numerous animal models 
lacking or overexpressing LCAT, including mice ( 6–10 ), 
hamsters ( 11 ), rabbits ( 12 ), and monkeys ( 13 ) have been 
generated to gain better insight in the complex role of 
LCAT in modulating lipoprotein metabolism, RCT, and 
atherosclerosis. 
 LCAT STRUCTURE AND FUNCTION 
 The human LCAT gene is localized in the q21–22 region 
of chromosome 16. It consists of 6 exons separated by 5 
introns and encompasses a total of 4.2 kb ( 14, 15 ). In 1986, 
it was sequenced and cloned for the fi rst time ( 16, 17 ). 
The gene encodes for a polypeptide chain, consisting of 
416 amino acid residues with an apparent molecular mass 
of approximately 60 kDa. LCAT is a glycoprotein with 
four N-glycosylation (Asn20, 84, 272, and 384) and two 
O-glycosylation sites (Thr407 and Ser409) ( 18 ). The car-
bohydrate content is   25% of its total mass, with the ma-
jority being N-linked ( 19 ). Removal of the carbohydrate 
moieties of isolated human LCAT by neuraminidase is as-
sociated with a 60% increase in the enzymatic activity ( 20 ). 
However, inhibition of glycosylation in Chinese hamster 
ovary (CHO) cells reduced the enzymatic activity without 
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 In 1935, Sperry was the fi rst to recognize that when hu-
man plasma was incubated at 37°C, a marked esterifi ca-
tion of free cholesterol occurred ( 1 ). He attributed this to 
enzymatic activity, as the effect was abolished when the 
plasma was heated to 55–60°C. Subsequent work by Glom-
set led in 1962 to the identifi cation of the lecithin:cholesterol 
acyltransferase (LCAT) enzyme, which accounts for the 
synthesis of most of the cholesterol esters in plasma ( 2 ). 
Four years later, Glomset identifi ed LCAT as an important 
driving force behind the reverse cholesterol transport (RCT) 
pathway ( 3 ), a process that describes the HDL-mediated 
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at the  sn -2 position of phosphatidylcholine (or lecithin) to 
the free hydroxyl group of cholesterol ( 15, 39 ). During 
this reaction, lecithins are converted into lysophosphati-
dylcholines. The transfer process occurs in multiple steps. 
First, apoAI “activates” the phospholipid-cholesterol bi-
layer by concentrating the lipid substrates near LCAT and 
presenting it in an optimal conformation to LCAT. The 
conformation of these apoAI complexes is affected by 
the fl uidity of the lipid bilayer ( 40, 41 ). Furthermore, the 
binding of LCAT to the apoAI bilayer is infl uenced by the 
size and charge of the HDL particles ( 42 ). The second 
step involves the cleavage of the  sn -2 ester bond of lecithin, 
leading to the release of a fatty acyl ( 24 ). This step is medi-
ated by the phospholipase activity of LCAT and depends 
on the lecithin composition ( 42 ). The last step includes 
the transacylation of the fatty acyl moiety to the sulfur 
atom of a cystein residue forming a thioester, which subse-
quently donates its fatty acyl to the 3  -hydroxy group of 
the cholesterol molecule, thereby forming cholesteryl es-
ter ( 24 ). In addition to apoAI, other apolipoproteins, such 
as apoAII, apoAIV, apoCI–III, and apoE, can activate 
LCAT, although less effi ciently ( 43 ). Two distinct types of 
LCAT activity can be distinguished:   and   .   -Activity de-
scribes the enzymatic activity of LCAT toward cholesterol 
bound to apoAI-containing lipoproteins (e.g., HDL parti-
cles).   -Activity constitutes the enzymatic activity of LCAT 
toward cholesterol bound to apoB-containing lipoproteins 
(e.g., VLDL and LDL particles) ( 44 ). The equilibrium dis-
sociation constants (Kd) for the interaction of pure hu-
man LCAT with LDL, HDL 2 , HDL 3 , and reconstituted 
discoidal HDL (rHDL) are as follows: rHDL = HDL 3   
HDL 2 < LDL with relative reactivities (app.  V max /app.  K m ) 
of 100, 16, 1, 6%, respectively ( 45 ). Hence, only a minority 
of LCAT in the circulation is bound to apoB-containing 
lipoproteins. 
 LCAT: MAIN DRIVING FORCE BEHIND REVERSE 
CHOLESTEROL TRANSPORT? 
 Already in 1966, Glomset identifi ed LCAT as an impor-
tant driving force behind the RCT pathway ( 3 ), a process 
that describes the HDL-mediated removal of excess cho-
lesterol from peripheral tissues, including macrophages 
from the arterial wall, and subsequent delivery to the liver 
for biliary excretion ( Fig. 1 ). 
 The fi rst step of the RCT pathway involves production of 
apoAI in the liver or intestine that is then released into the 
plasma ( 46 ). Interaction with ATP-binding cassette trans-
porter (ABC)A1 on primarily the liver and intestine in-
duces the formation of nascent discoidal HDL (ndHDL) 
particles that can stimulate cholesterol effl ux from mac-
rophages in the arterial wall ( 47, 48 ). Upon association of 
cholesterol with the ndHDL particle, it is esterifi ed by 
LCAT, leading to partitioning of the cholesterol esters into 
the core of the particle and conversion of the ndHDL into 
a more mature HDL 3 particle. This particle subsequently is 
able to induce effl ux of cellular cholesterol via ABCG1 and 
SR-BI ( 47, 48 ). Upon further enrichment of the HDL 
affecting LCAT protein secretion ( 19 ). The biological sig-
nifi cance of the two O-glycosylation sites is largely unclear. 
Site-directed mutagenesis studies in transfected COS-6 
cells by substitution of Asn with Thr showed that N-linked 
glycosylation at Asn272 is indispensible for secretion of ac-
tive LCAT, whereas Asn84 is critical for its full activity but 
not for intracellular processing ( 21 ). In another study by 
Karmin and colleagues, the effect of substitution of the 
Asn residues with Gln was investigated in COS-1 cells ( 22 ). 
These studies showed that glycosylation at all four sites is 
required to generate the full-size mature LCAT protein, 
but deletion of only one of the N-linked glycosylation sites 
does not affect intracellular processing and secretion. The 
pattern of N-linked glycosylation, however, has profound 
effects on the catalytic activity of the enzyme. Substitution 
of Asn84 or Asn272 with Gln led to 82% and 62% decrease 
in activity, respectively, whereas replacement of Asn384 
led to substantially increased activity ( 21 ). Furthermore, 
N-glycosylation is important for determining substrate 
specifi city toward native HDL and LDL ( 23 ). 
 No X-ray structure of the LCAT protein has been pub-
lished. By use of selective chemical modifi cation and stoi-
chiometric analysis, it was shown that a single serine and a 
single histidine mediate lecithin cleavage and that the two 
free cysteines participate as transient fatty acyl acceptors in 
cholesterol esterifi cation ( 24–26 ). The fi rst structural 
model of LCAT was proposed by Yang and colleagues in 
1987 based upon the primary structure, chemical modifi -
cation, homology with other proteins, and enzymatic as-
says ( 27 ). Furthermore, 3D modeling based on its homology 
with other members of the    -hydrolase superfamily has 
shown that LCAT contains a catalytic triad consisting of 
three amino acid residues, serine (Ser), aspartic acid 
(Asp), and histidine (His) at positions 181, 345, and 377 
( 28–30 ). Recently, using a combination of several new and 
improved fold-recognition methods, Holleboom and col-
leagues confi rmed this model with, according to the new 
protein nomenclature, residues Ser205, Asp369, and 
His401 forming the catalytic triad of LCAT ( 31 ). LCAT 
contains six cysteine residues, of which four are located at 
the active site of the protein and are used to form two dis-
ulfi de bridges (Cys50–Cys74 and Cys313–Cys356) ( 27, 32 ). 
The disulfi de-linked Cys50–Cys74 residues span the lid re-
gion of LCAT that covers the catalytic site of LCAT and 
opens upon binding to lipoprotein surfaces ( 33 ). 
 The human LCAT protein is synthesized primarily by 
the liver, although it is also expressed in small amounts in 
the testes and in astrocytes in the brain, where it is involved 
in the esterifi cation of cholesterol in glia-derived apoE-
containing lipoproteins ( 15, 27, 34, 35 ). The plasma con-
centration of LCAT is about 6   g/ml and varies little in 
adult humans with age, gender, and smoking ( 36 ). The 
half-life of human LCAT in plasma has been estimated to 
be 4–5 days ( 37 ) LCAT reversibly binds to lipoproteins 
and is primarily found on HDL, which likely prevents its 
rapid clearance from the circulation ( 38 ). ApoAI is the 
most potent activator of LCAT, which enables it to convert 
free cholesterol into cholesteryl esters on HDL by a trans-
esterifi cation reaction involving the transfer of a fatty acid 
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 However, there are several reasons to question whether 
LCAT is the main driving force for the RCT pathway. First, 
LCAT-defi cient patients only show accumulation of cho-
lesterol in specifi c cells/organs, including erythrocytes, 
kidney, and cornea ( 58 ). Second, passive diffusion was 
previously considered the predominant mechanism of cel-
lular cholesterol effl ux, but now facilitated transport via 
ABCA1, ABCG1, and SR-BI is recognized to be essential 
( 47, 48 ). Although cellular cholesterol effl ux via SR-BI is 
dependent on the cellular free cholesterol gradient ( 59 ), 
active ATP-powered transport via ABCA1 and ABCG1 is 
not and, hence, is less likely to be dependent on LCAT 
activity. Third, adenoviral-mediated overexpression of 
murine LCAT in livers of C57Bl/6 mice did not stimulate 
cholesterol effl ux from extraheptic tissues despite the 
accumulation of large cholesteryl ester-rich HDL particles 
in the circulation ( 60 ). Fourth, human LCAT overexpres-
sion in mice does not enhance macrophage RCT in vivo, 
and LCAT-defi cient mice display largely preserved mac-
rophage RCT despite marked reductions in plasma HDL 
cholesterol ( 61 ). Fifth, serum from carriers of LCAT gene 
mutations has the same capacity as control serum to decrease 
the cholesterol content of cholesterol-loaded macrophages 
particles with cholesteryl ester, they are transformed into 
larger HDL 2 particles ( 46 ). Several studies indicate that 
LCAT activity decreases upon enlargement of the HDL 
particle, particularly on large apoE-rich HDL 1 particles 
( 49–52 ). This might be a direct effect of the fact that LCAT 
is subject to product inhibition ( 45 ), but it has also been 
suggested that sphingomyelin enrichment of HDL pre-
vents binding of LCAT to the lipoprotein ( 49, 53 ). Impor-
tantly, upon esterifi cation of cholesterol in HDL, LCAT 
maintains the gradient of free cholesterol between the cel-
lular membrane and the surface of the HDL particle, which 
is thought to generate a continuous fl ow of cholesterol 
from the cell to lipoproteins and prevent the transfer of 
cholesterol back to the cell ( 54–56 ). The latter ( i.e., pre-
vention of reuptake of cholesterol by the cell) is nowadays 
considered the most important pathway via which LCAT 
stimulates HDL-mediated effl ux. Importantly, it is also pos-
tulated that the effect of LCAT on the fl ux of cholesterol 
may depend both on the type and metabolic status of the 
cells, and on the environment of HDL in the extracellular 
medium ( 57 ). Therefore, in addition to its essential role in 
the fi rst step of the RCT pathway, LCAT is suggested to 
enhance the delivery of cholesterol to the liver ( 57 ). 
 Fig.  1. LCAT functions potentially affecting the pathogenesis of cardiovascular disease. LCAT is considered an important driving force 
behind the RCT pathway, a process that describes the HDL-mediated removal of excess cholesterol from peripheral tissues, including mac-
rophages in the arterial wall, and subsequent delivery to the liver for biliary excretion. Upon association of cholesterol with ndHDL parti-
cles, it is esterifi ed by LCAT, leading to partitioning of the cholesterol esters into the core of the particle and conversion of the ndHDL into 
mature HDL 3 or HDL 2 particles. Upon esterifi cation of cholesterol in HDL, LCAT maintains the gradient of free cholesterol between the 
cellular membrane and the surface of the HDL particle, which is thought to generate a continuous fl ow of cholesterol from the cell to li-
poproteins and prevent the transfer of cholesterol back to the cell. In addition to its essential role in the fi rst step of the RCT pathway, LCAT 
is suggested to enhance the delivery of cholesterol to the liver. Furthermore, LCAT directly or indirectly interferes with several other physi-
ological processes that might affect the development of atherosclerosis, including HDL antioxidant function by hydrolyzing oxidized 
phospholipids in oxidized LDL (oxLDL), adrenal steroidogenesis, insulin sensitivity and protection against obesity, and platelet function. 
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whether LCAT-defi cient patients suffer more frequently 
from adrenal insuffi ciency. However, carriers of LCAT 
mutations display lower total urinary 17-ketogenic steroids 
and 17-hydroxycorticoids ( 73 ). 
 LCAT defi ciency in mice is associated with enhanced in-
sulin sensitivity ( 74, 75 ). Furthermore, recently it was re-
ported that LCAT-defi cient mice, especially females, are 
protected against high-fat high-sucrose (HFHS) diet-
induced obesity ( 76 ). These protective metabolic pheno-
types are associated with protection against diet-induced 
hepatic and adipocyte endoplasmic reticulum (ER) stress, 
but the mechanistic link with the enzymatic action of 
LCAT needs further investigation. Currently it is unknown 
whether LCAT-defi cient (female) patients are more insu-
lin sensitive and/or protected against obesity. An early 
study showed that both fractional and molar LCAT rates 
were positively correlated with obesity in women but not in 
men ( 77 ). However, another more recent study found in-
creased plasma LCAT in obese individuals of both sexes 
( 78 ). Furthermore, the plasma LCAT activity level was 
shown to be positively related to insulin resistance in asso-
ciation with a higher body mass index (BMI) in a group of 
32 Dutch men ( 79 ). In the IMPROVE study with individu-
als at high risk for developing cardiovascular disease, no 
link between LCAT quartiles and BMI or occurrence of 
diabetes was found ( 80 ). Considering that obesity is the 
epidemic of the twenty-fi rst century and is a prominent 
risk factor for cardiovascular disease, the link between 
LCAT, insulin resistance, and obesity warrants further 
investigation. 
 Acute coronary events are not the result of progres-
sive growth of the lesion but, rather, of lesion disruption 
and superimposed thrombus formation in which plate-
lets are key elements. Platelets from two LCAT-defi cient 
patients did not show alterations in the cholesterol:
phospholipid ratio ( 81 ), indicating that impaired cho-
lesterol esterifi cation does not raise free cholesterol in 
the platelets. However, binding of thrombin, a strong 
activator of platelet aggregation, was elevated in plate-
lets from LCAT-defi cient patients (n = 2). In agreement, 
one patient showed increased platelet thrombin-in-
duced aggregation responses, but aggregation in an-
other was decreased. The effects of LCAT defi ciency on 
platelet activation are thus inconclusive, and studies in 
more patients and characterizing the different aspects 
of platelet function, including, for example, aggrega-
tion responses to different agonists and adhesion under 
fl ow, are awaited. 
 In summary, in addition to its role in RCT, LCAT di-
rectly or indirectly interferes with several other physio-
logical processes that might affect the development of 
atherosclerosis ( Fig. 1 ). Future studies delineating the 
exact contribution of the effects of LCAT on HDL anti-
oxidant/anti-infl ammatory function, adrenal steroido-
genesis, insulin sensitivity and protection against obesity, 
and platelet function are expected to shed more light on 
the importance of these processes compared with 
LCAT’s role in RCT for the pathogenesis of cardiovascu-
lar disease. 
due to a greater cholesterol effl ux capacity via ABCA1 ( 62, 
63 ). Finally and most importantly, the role of LCAT as an 
atheroprotective factor is under debate. 
 OTHER FUNCTIONS OF LCAT POTENTIALLY 
AFFECTING CVD 
 LCAT also transesterifi es and hydrolyzes platelet-activat-
ing factor and oxidized phospholipids with long chains in 
the  sn -2 position ( 64–66 ). Thus, LCAT is expected to con-
tribute to the antioxidant/anti-infl ammatory properties 
of HDL ( 67 ). In agreement, in contrast to HDL from 
healthy volunteers, HDL from LCAT heterozygotes (n = 
12) is unable to inhibit the oxidation of LDL, whereas 
HDL from compound heterozygotes (n = 3) and a ho-
mozygote appeared to induce more oxidation ( 68 ). Fur-
thermore, HDL of LCAT heterozygotes, compound 
heterozygotes, and a homozygote had 50% ( P = 0.040), 
166% ( P < 0.0001), and 1280%, respectively, higher levels 
of malondialdehyde than controls, indicating increased 
oxidation. The HDL-associated LCAT activity was de-
creased by 39% in heterozygotes, and 94% and 80% in the 
compound heterozygotes and homozygote, respectively. 
In the latter groups, however, the HDL-associated PAF-AH 
activity was also reduced by 54%. Isolated human HDL 
contains some 50 different proteins ( 69 ) and a complex 
range of 100 small peptides ( 70 ). Considering that the 
consequences of LCAT defi ciency for the complete HDL 
proteome are unknown, it is currently unclear whether 
the effects of LCAT defi ciency on the antioxidant proper-
ties of HDL are a direct effect of the impaired LCAT func-
tion or due to other anomalies of the HDL proteome. 
However, because oxidation of plasma lipoproteins is an 
important event in the formation of atherogenic particles, 
impaired LCAT function is anticipated to induce the 
pathogenesis of atherosclerosis. 
 Recently, evidence was provided that SR-BI-mediated 
uptake of cholesterol from HDL by the adrenal is essential 
to acquire cholesterol for the production of glucocorti-
coids, both in mice and in humans ( 71, 72 ). Adrenals from 
LCAT-defi cient mice are severely depleted of cholesterol 
stores, similarly as previously reported for SR-BI knockout 
mice ( 10 ). As LCAT is not expressed in adrenal ( 27 ), the 
most likely cause for the reduced lipid content of the ad-
renal is the severe depletion of plasma HDL cholesterol. 
In humans, LDL receptor-mediated uptake of LDL was 
long considered the primary pathway for delivery of cho-
lesterol from the circulation to the adrenal. However, re-
cently we found that subjects with an SR-BI c.889C → T 
missense gene variant, which leads to a proline-to-serine 
substitution at the highly conserved position 297 (P297S), 
showed attenuated adrenal steroidogenesis, indicating 
that also in humans SR-BI-mediated uptake of lipopro-
teins, likely HDL, is essential for adrenal function ( 71 ). 
Because glucocorticoids have important anti-infl amma-
tory properties, altered glucocorticoid production in re-
sponse to infl ammation in the arterial wall might infl uence 
the progression of the disease. It is currently unknown 
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 Partial LCAT defi ciency leads to fi sh-eye disease, a less 
severe syndrome compared with FLD. The name refers to 
a symptom that FED as well as FLD patients often develop: 
the eyes resemble the eyes of boiled fi sh due to age-depen-
dent opacifi cation of the cornea ( 88 ). Other characteris-
tics of FED are low HDL cholesterol, elevated triglyceride 
(TG) levels, and multiple lipoprotein abnormalities 
( 88–91 ). The most signifi cant difference between the two 
LCAT defi ciency syndromes is that patients with FLD suf-
fer from a complete lack of LCAT activity, whereas patients 
with FED have a partial reduction in LCAT activity ( 88, 
89 ). The latter have LCAT with a reduced ability to esterify 
cholesterol bound to HDL, but esterifi cation of choles-
terol bound to other lipoproteins (e.g., VLDL and LDL) 
is normal. Thus, the   -activity of LCAT is lost, while its 
  -activity is preserved ( 92 ). 
 In 1997, Kuivenhoven et al. proposed a new classifi ca-
tion system for natural LCAT mutations based on the dif-
ferent biochemical and clinical phenotypes observed in 
LCAT-defi cient patients, as well as the biochemical charac-
teristics of mammalian cell cultures expressing the mu-
tants of the LCAT gene ( 44 ). Importantly, this new system 
allows the classifi cation of heterozygous mutations that led 
to confusion in the previous FLD/FED classifi cation sys-
tem ( 93, 94 ). Intermediate phenotypes due to mutations 
not causing a total loss of LCAT activity (FLD) but causing 
more than “just” partial loss of LCAT activity against HDL 
(FED) are also taken into account ( 95, 96 ). For the in vivo 
classifi cation, fi ve criteria were proposed:  i ) LCAT activity 
toward HDL analogs;  ii ) cholesterol esterifi cation rate 
(endogenous lipoproteins);  iii ) ratio of plasma FC to EC; 
 FAMILIAL LCAT DEFICIENCY AND FISH-EYE 
DISEASE 
 LCAT defi ciency syndromes are rare metabolic disor-
ders with an autosomal recessive mode of inheritance ( 82 ) 
that arise as a consequence of either a defect in the en-
zyme or defects in its synthesis and/or secretion. Individu-
als with deleterious mutations on both alleles present with 
HDL defi ciency, whereas heterozygotes typically have HDL 
cholesterol levels that are half of normal HDL cholesterol 
( 82, 83 ). Two important LCAT defi ciency syndromes can 
be distinguished:  i ) familial LCAT defi ciency (FLD) and 
 ii ) fi sh-eye disease (FED) ( Fig. 2 ).  FLD was reported for 
the fi rst time in 1967 in a Norwegian family. In this family, 
three adult sisters showed extremely low plasma LCAT ac-
tivity, reduced levels of cholesteryl esters, and reduced 
plasma LCAT concentration ( 4 ). The clinical features in-
cluded proteinuria, normochromic anemia, corneal opac-
ity ( 84 ), and turbid milky plasma. Furthermore, foam cells 
were found in the bone marrow and kidney, and lipid al-
terations were found in the erythrocytes ( 85 ). Years later, 
it was established that homozygosity for a single nucleotide 
substitution in codon 252 of exon 6 in the gene, leading to 
the exchange of a methionine (ATG) for a lysine residue 
(AAG), was responsible for the LCAT defi ciency in this 
family ( 86 ). In vitro experiments showed that this muta-
tion led to the production of a fully inactive LCAT enzyme 
( 87 ). In general, FLD is characterized by HDL defi ciency 
and lipid changes in both VLDL and LDL levels. Impor-
tant clinical features are corneal opacifi cation, mild ane-
mia, and progressive loss of renal function ( 82 ). 
 Fig.  2. LCAT defi ciency syndromes. Two important LCAT defi ciency syndromes can be distinguished:  i ) 
familial LCAT defi ciency (FLD) and  ii ) fi sh-eye disease (FED). The most signifi cant difference between the 
two syndromes is that patients with FLD suffer from a complete lack of LCAT activity, whereas patients with 
FED have a partial reduction in LCAT activity. Both FED and FLD patients have a reduced ability to esterify 
cholesterol bound to HDL (i.e., impaired   -activity). In contrast to FLD, in FED esterifi cation of cholesterol 
bound to other lipoproteins like VLDL and LDL (  -activity of LCAT) is preserved. Adapted from Hill ( 87 ). 
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contained numerous lipid-laden cells that are assumed to 
be partly responsible for the splenomegaly found in FLD 
patients. Notably, only 35% of the total cholesterol was es-
terifi ed in arterial lipid depositions of FLD patients com-
pared with 75% in normal atheromas. In 1982, Carlson 
showed that FED patients did not suffer from premature 
atherosclerosis in spite of the extremely low HDL choles-
terol levels ( 89 ). This was surprising, as FED patients have 
very low levels of HDL, and it thus was expected that these 
patients would have an increased risk for atherosclerosis. 
Four years later, it was demonstrated that patients with 
atherosclerosis (one- to three-vessel disease) had increased 
LCAT levels compared with healthy controls (clinical 
out-patients or hospital personnel) and patients without 
atherosclerosis (zero-vessel disease) ( 104 ). Furthermore, 
LCAT activity was augmented with increased severity of 
coronary atherosclerosis. The results of this study suggest 
that increased, rather than decreased, plasma LCAT activ-
ity is characteristic of coronary atherogenesis. Since then, 
the role of LCAT in the pathogenesis of atherosclerosis 
has been under debate. 
 LCAT and atherosclerosis in human FED and 
FLD patients 
 Atherosclerosis susceptibility has been extensively inves-
tigated in FED and FLD patients (see  Table 1 for over-
view).  Strikingly, in several of the studies no differentiation 
was made between the phenotypic differences of FED and 
FLD patients. LCAT activity is clearly reduced in FED and 
FLD patients, with the largest effects in patients with a ho-
mozygous LCAT mutation. FLD and FED patients present 
with nearly complete HDL defi ciency. However, heterozy-
gotes for LCAT mutations typically present with 35–50% 
reductions in HDL cholesterol levels. Furthermore, in sev-
eral studies, homozygous LCAT defi ciency was associated 
with a reduction in total cholesterol and LDL-C, although 
the fi ndings differ largely between the individual studies. 
In a number of the studies (but not all) a remarkable in-
crease in serum triglycerides was also found, especially in 
homozygous carriers of an LCAT mutation. Low HDL 
cholesterol levels are frequently associated with elevated 
levels of triglyceride-rich lipoproteins in the general pop-
ulation ( 105 ). Conversely, postprandial and fasting hyper-
triglyceridemia lead to low HDL ( 106, 107 ). The direct 
cause of the increased triglycerides in some LCAT-defi -
cient patients has not been extensively studied. One study 
by Frohlich and colleagues showed that postheparin lipo-
protein lipase activity was reduced in two homozygous 
LCAT-defi cient patients ( 108, 109 ), but it is unknown 
whether triglyceride absorption or synthesis was affected 
in these patients. 
 Considering the low HDL cholesterol levels and often 
increased triglyceride levels, one would expect that carri-
ers of LCAT mutations would be at increased risk for de-
veloping cardiovascular disease. Indeed, cases have been 
described indicating dramatically increased atheroscle-
rotic burden. Scarpioni and colleagues described in 2008 
an interesting patient with FLD, who developed severe vas-
cular disease, as evidenced by lower limb peripheral arterial 
 iv ) plasma LCAT concentration; and  v ) clinical symptoms 
of the disease. For the in vitro experiments, two criteria 
were proposed:  i ) specifi c activity of mutant protein to-
ward HDL analogs and native LDL and  ii ) activity of mu-
tant protein toward heat-inactivated plasma ( 44 ). The 
classifi cation system describes fi ve classes. The fi rst class 
contains null mutations of the LCAT gene. This means 
that patients in this class display a total loss of catalytic ac-
tivity of LCAT and that they have the clinical phenotype of 
FLD. The second class contains missense mutations that 
cause complete or nearly complete loss of catalytic activity 
of the LCAT gene. The third class contains both missense 
mutations and minor deletions in the LCAT gene that are 
responsible for an intermediate phenotype, meaning that 
there is either partial loss of activity against LDL or com-
bined partial loss of activity against both HDL and LDL. 
This class thus also includes patients who show FED symp-
toms but do not develop all the symptoms of the FLD syn-
drome . The fourth class contains the mutations responsible 
for the typical symptoms of the FED syndrome. This class 
thus includes missense mutations that result in specifi c 
loss of activity against HDL analogs, but activity against 
LDL or other apoB-containing lipoproteins is preserved. 
The fi fth class contains three mutations that the group of 
Kuivenhoven et al. was unable to categorize; therefore, this 
category was named “unclassifi ed mutations.” 
 To date, approximately 60 isolated cases and 70 small 
families with partial or complete LCAT defi ciency have 
been described with 86 different molecular defects in the 
LCAT gene ( 5 ) (http://www.hgmd.org). LCAT defi ciency 
is a rare disorder. In general, the prevalence of LCAT mu-
tations in subjects with low HDL cholesterol has been esti-
mated at 2–16% ( 97–100 ) in Finnish and Caucasian 
Canadian patients, respectively. In the recently published 
results of the Copenhagen City Heart Study, in which the 
regulatory and coding regions of LCAT were resequenced 
in individuals with the 2% lowest (n = 180) plasma HDL 
cholesterol levels, no carriers of loss-of-function mutations 
in LCAT were identifi ed, indicating that these are ex-
tremely rare in the general population ( 101 ). In the Neth-
erlands, however, functional mutations in LCAT were 
found in almost one third (29%) of patients with low HDL 
cholesterol, thus constituting a common cause of low HDL 
cholesterol in referred patients in this country ( 31 ). Inter-
estingly, a recent genome-wide association study (GWAS) 
in more than 100,000 individuals of European ancestry 
identifi ed a single-nucleotide polymorphism (SNP) in 
LCAT as the strongest marker of isolated variation in HDL 
cholesterol levels ( 102 ). 
 LCAT AND ATHEROSCLEROSIS IN HUMAN 
STUDIES 
 As LCAT was considered the main driving force in the 
RCT pathway, it was soon thought that the enzymatic activ-
ity of LCAT could be involved in the protection against 
atherosclerotic lesion formation. In 1973, Hovig and 
Gjone demonstrated lipid deposition in renal arteries and 
veins of patients with FLD ( 103 ). Furthermore, the spleen 
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compound heterozygous carriers and 28 heterozygous 
carriers) and 80 matched nonfamily controls ( 63 ). Unad-
justed average cIMT was 0.50 mm (0.44–0.56 mm) in carri-
ers of two mutant alleles and 0.62 mm (0.57–0.67 mm) in 
carriers of one mutant LCAT allele compared with 0.65 mm 
(0.62–0.68 mm) in matched controls. 
 Thus, in contrast to the studies in both Canadian and 
Dutch FED subjects, cIMT was decreased in Italian patients 
with FLD and FED, suggesting that functional LCAT is not 
required for effi cient atheroprotection in this population. 
These contradictory outcomes are diffi cult to explain, but 
may result from differences in the populations studied. In 
addition, a limitation of cIMT analysis is that carotid ultra-
sound lacks statistical power to reliably measure arterial 
wall thickness in small population studies because it pro-
vides 2-dimensional longitudinal images, whereas athero-
sclerosis is a 3-dimensional eccentric developing disease. 
 In a recent study, Duivenvoorden et al. used 3.0-Tesla 
carotid magnetic resonance imaging, which allows trans-
verse 3-dimensional imaging of atherosclerosis at high 
resolution, to investigate the role of reduced LCAT func-
tion on atherogenesis ( 98 ). In this study, 40 subjects (38 
heterozygotes and 2 homozygotes) with mutations in the 
gene for LCAT were compared with 40 controls (both 
family members and unrelated individuals) matched for 
age and cardiovascular risk factors ( 111, 112 ). The carriers 
had 10% higher normalized wall index and 20% higher 
mean wall area and total wall volume. In addition, 50% of 
the carriers, compared with only 8% of controls, had ath-
erosclerotic plaque components defi ned as either lipid-
rich tissue or calcifi ed material, and total plaque volume 
was signifi cantly increased (102 mm 3 versus 3 mm 3 in car-
riers versus noncarriers, respectively). Despite the encour-
aging results from this particular study, it should be noted 
that due to the rarity of the disorder, the number of sub-
jects investigated is relatively small and no conclusions can 
be drawn on hard cardiovascular end points. 
 LCAT and atherosclerosis in the general population 
 Only a few studies examining genetic variants in the 
general population have been described. Very recently, in 
obstruction with necrosis of two toes of his left foot and 
angina at rest with trivasal occlusive coronary artery dis-
ease at coronarography ( 110 ). Eventually this patient died 
at the age of 42 after a right femoral-axillo artery bypass 
and a thigh amputation. This is a single case illustrating 
that LCAT-defi cient patients can suffer from premature 
atherosclerosis. As indicated in  Table 1 , cardiovascular dis-
ease (CVD) and increased carotid intima-media thickness 
(cIMT), a surrogate marker of CVD, have been reported 
in several other FLD and FED patients. However, many 
patients do not show an apparent increased risk for devel-
oping clinically apparent disease. Very recently, Tietjen 
et al. reported that 16 out of 38 (42.1%) LCAT loss-of-
function mutation carriers from Dutch and Canadian 
descent with HDLc < 5 th percentile had CAD, whereas no 
signifi cant increase in risk was observed in mutation carri-
ers with HDLc > 5 th percentile ( 100 ). 
 The effects of LCAT defi ciency on cIMT have been stud-
ied using ultrasound imaging in three relatively large stud-
ies. In 2004, Ayyobi and colleagues published a 25-year 
follow-up study of a Canadian kindred with two homozy-
gous (average age 42 at the end of the study) and nine 
heterozygous (average age 39) FLD patients ( 109 ). Over 
the 25 years of the study, there had been no vascular events 
or deaths in the family, but this might be due to the rela-
tively young age of the studied individuals. In the two 
homozygotes, the cIMT was above the 75 th percentile ex-
pected for age and gender (0.721 mm versus expected 
0.647 mm). However, the cIMT abnormalities were much 
more pronounced in the heterozygotes (0.898 ± 0.296 mm 
versus expected 0.662 ± 0.132), four of whom also had de-
tectable plaques. 
 In a second study by Hovingh and colleagues, cIMT val-
ues were assessed in 47 Dutch heterozygotes for LCAT 
gene mutations causing FED and 58 family controls ( 83 ). 
Mean cIMT was increased in heterozygotes compared with 
family controls (0.623 ± 0.13 versus 0.591 ± 0.08 mm), 
which became statistically signifi cant ( P < 0.0015) after ad-
justment for age, gender, and alcohol use. 
 Third, Calabresi and colleagues investigated cIMT in 30 
Italian FLD and FED patients (of which 12 homozygous or 
 TABLE 1. Effects of LCAT loss-of-function mutations on the development of atherosclerosis in humans 
Study FED/FLD Atherosclerosis-Related Effect
( 103 ) FLD Lipid deposition in renal arteries and veins Antiatherogenic?
( 89 ) FED No signs of premature atherosclerosis ?
( 145 ) FED No signs of atherosclerosis in FED patients ?
( 146 ) FED No signs of atherosclerosis in FED patients ?
( 96 ) FED Premature coronary artery disease observed in homozygous 
 male probands
Antiatherogenic
( 147 ) FED Patient with premature coronary artery disease in the absence 
 of other risk factors
Antiatherogenic
( 148 ) FLD FLD patient associated with marked atherosclerosis Antiatherogenic
( 109 ) FLD Heterozygosity for LCAT defi ciency associated with increased cIMT Antiatherogenic in heterozygotes
( 149 ) FLD+FED No signs of premature cardiovascular disease ?
( 83 ) FED Increased cIMT in heterozygotes Antiatherogenic
( 97 ) FLD Severe vascular disease with peripheral arterial obstruction and 
 occlusive coronary artery disease
Antiatherogenic
( 110 ) FED+FLD Decreased cIMT Proatherogenic
( 111 ) FED+FLD Carriers of LCAT gene mutations have increased carotid 
 atherosclerosis compared with controls
Antiatherogenic
( 100 ) FED+FLD Increased risk for CAD with HDL< 5 th percentile Antiatherogenic if HDL < 5 th percentile
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cases ( P = 0.027) in association with higher total choles-
terol, non-HDL cholesterol, and triglycerides; thus, high 
plasma LCAT activity did not predict reduced CVD risk. 
In the EPIC-Norfolk population study, plasma LCAT lev-
els, which strongly correlate with LCAT activity, were mea-
sured in 933 apparently healthy men and women who 
developed cardiovascular disease and 1,852 matched con-
trols who remained free of CVD during 6-year follow-up 
( 117 ). Mixed-gender analyses showed no association be-
tween plasma LCAT levels and future cardiovascular 
events. However, high LCAT levels were associated with 
an increased CVD risk in women, whereas in males an op-
posite nonsignifi cant trend was observed. It is possible 
that the opposite trends in men and women underlie the 
absence of a relation between LCAT levels and CVD in 
the mixed-gender studies. In agreement, in a recent study 
by Calabresi and colleagues ( 80 ) gender-specifi c analysis 
of 247 European women of the multicenter IMPROVE 
study showed that low plasma LCAT levels were associ-
ated, although with borderline signifi cance, with de-
creased cIMT in women with high cardiovascular risk. In 
the entire cohort and in men, no association between 
cIMT and LCAT levels was found. Currently, it is not clear 
how low levels of LCAT would protect against CVD in 
women but not in men. Other gender-specifi c prospective 
studies should confi rm the fi ndings, and it is hoped that 
further mechanistic studies provide the mechanistic rea-
son in the near future. Importantly, the fi ndings in CVD 
patients do not support the presumed antiatherogenic 
the Copenhagen City Heart Study and the Copenhagen 
General Population Study, LCAT S208T, a common vari-
ant identifi ed in individuals with the lowest 2% HDL cho-
lesterol, was found to be associated with a 13% decrease in 
HDL cholesterol (n = 85) but not with increased risk of 
myocardial infarction or other ischemic end points ( 101 ). 
In contrast, in Chinese CVD patients, P143L, a single-
nucleotide polymorphism (SNP) in exon 4 of the LCAT 
gene, was discovered previously in nine males and two fe-
males (frequency of 5.8%), which was associated with low 
HDL cholesterol ( 113 ). Furthermore, Pare and colleagues 
identifi ed an LCAT regulatory SNP, rs2292318, which was 
associated both with HDL cholesterol and plasma triglyc-
eride levels ( 114 ). Interestingly, the minor allele was the 
“protective” allele with regard to CVD. In a smaller valida-
tion sample, no statistically signifi cant association with 
HDL was found, although the fi ndings were consistent 
with the direction of the original association. 
 Several studies also addressed the association between 
LCAT activity and concentration in patients with cardio-
vascular disease ( Table 2 ).  Unfortunately, the results from 
these studies are far from conclusive. In early studies, ei-
ther reduced ( 115 ) or increased ( 104 ) LCAT activity was 
found in patients with CVD. More recently, in a commu-
nity-based prospective nested case-control study (PRE-
VEND cohort), an exogenous substrate assay was used to 
measure plasma LCAT activity in 116 men who developed 
CVD (cases) and in 111 male controls ( 116 ). In this co-
hort, plasma LCAT activity was found to be 5% higher in 
 TABLE 2. LCAT in patients with cardiovascular disease 
Study Study Design Disease
LCAT Activity
(nmol/ml/h) Atherosclerosis-Related Effect
( 104 ) Male CVD patients Control No lesion Single vessel 
 Double vessel Triple vessel 
 Myocardial infarction
91
84
126
121
125
80
Increased LCAT in subjects 
 with increased atherosclerosis 
 severity
Proatherogenic
( 115 ) CVD patients No lesion Single vessel 
 Double vessel Triple vessel
107
55
32
16
Reduced LCAT in subjects 
 with increased atherosclerosis 
 severity
Antiatherogenic
( 116 ) PREVEND a Control (men) Case (men) 111
116
High plasma LCAT activity 
 does not predict reduced 
 CVD risk, and may attenuate 
 cardioprotection associated 
 with higher HDL cholesterol.
Possibly proatherogenic
Odds ratio for CAD LCAT quartiles
( 117 ) EPIC-NORFOLK b Men: 1 Women: 1 1 Decreased risk of CAD with 
 increasing LCAT levels in 
 men, while the risk of CAD in 
 women increased with 
 increasing LCAT levels.
Antiatherogenic in men 
 Proatherogenic in womenMen: 0.83 Women: 0.88 2
Men: 0.75 Women: 1.14 3
Men: 0.71 Women: 1.35 4
cIMTmax (mm)
( 80 ) IMPROVE c Men: 1.35 Women: 1.19 1 Low plasma levels of LCAT 
 associated with decreased 
 cIMT in women, but not 
 in men
Proatherogenic in women, 
 but not in menMen: 1.37 Women: 1.22 2
Men: 1.33 Women: 1.23 3
Men: 1.35 Women: 1.27 4
 a Prevention of Renal and Vascular End-stage Disease (PREVEND) study of 40,856 inhabitants (age range at recruitment, 28–75 years) in 
Groningen, The Netherlands.
 b European Prospective Investigation into Cancer and Nutrition (EPIC-NORFOLK) of over 30,000 inhabitants (age range at recruitment, 45–74 
years) in Norfolk, UK.
 c Prospective, multicentre , longitudinal, observational study of 3,711 subjects (age range, 54–79 years) with at least three vascular risk factors 
recruited in seven centers in Finland, France, Italy, the Netherlands, and Sweden.
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 Mehlum and colleagues generated C57Bl/6 mice con-
taining the full-length human LCAT gene, including 
0.1932 kb of the 5 ′ fl anking region and 0.908 kb of the 3 ′ 
fl anking region ( 8 ). About 30 copies of the transgene were 
integrated into one site.   -LCAT activity was increased 
from 106 nmol/ml/h in controls to 4,431 nmol/ml/h in 
the transgenics. Strikingly, the endogenous LCAT activity 
was only half that of controls (53   mol/ml/h in transgen-
ics compared with 106   mol/ml/h in controls), which was 
attributed to substrate inhibition of LCAT or lack of avail-
able free cholesterol in a suitable compartment. 
 In all three studies, overexpression of human LCAT in-
creased total cholesterol, primarily because of an increase 
in the amount of cholesterol esters transported by HDL. 
As a result of the enhanced esterifi cation of free choles-
terol in HDL, abnormally large HDL particles that were 
rich in apoE accumulated in the circulation of these ani-
mals ( 6 ). No effects were seen on serum triglycerides in 
the Vaisman study, whereas Francone et al. reported a 
2-fold lower triglyceriode content of HDL in human LCAT 
transgenics. Mehlum and colleagues found a similar but 
nonsignifi cant lowering of HDL triglycerides. Further-
more, a highly signifi cant 2-fold lowering of triglycerides 
was found in VLDL, the predominant transporter of trig-
lycerides in mice on chow diet, whereas triglycerides in 
LDL were 3-fold lower. 
 In  Table 3 ,  an overview is given of the studies investigat-
ing the effects of overexpression of human LCAT in mice 
on atherosclerosis susceptibility. Upon feeding a high-fat, 
high-cholesterol diet containing 15% fat, 1.25% choles-
terol, and 0.5% cholic acid for 16 weeks, Vaisman LCAT 
transgenic mice expressing 100 or 240 copies of the trans-
gene had signifi cantly higher plasma levels of total (1.2- to 
1.5-fold) and HDL cholesterol (1.6- to 3.3-fold), as well as 
apoAI (3.8- to 7.6-fold increase) ( 118 ). Plasma non-HDL 
cholesterol levels were not signifi cantly different, nor were 
apoB levels.   -LCAT activity under these conditions was 
1,283 and 2,908 nmol/ml/h, and endogenous LCAT activ-
ity was increased 2- to 3-fold compared with control ani-
mals. Feeding the Francone LCAT transgenic mice an 
function of LCAT and in females LCAT, if anything, might 
be proatherogenic. 
 LCAT AND ATHEROSCLEROSIS IN ANIMAL 
STUDIES 
 To gain better insight in the complex role of LCAT in 
modulating lipoprotein metabolism, RCT, and atheroscle-
rosis, multiple genetically modifi ed animal models have 
been developed, including transgenic and knockout mice 
and transgenic rabbits. 
 LCAT and atherosclerosis in human LCAT transgenic 
mouse models 
 In 1995, three independent groups published studies 
describing the effects of overexpression of human LCAT 
in mice. 
 Vaisman and colleagues generated transgenic mice 
containing the entire human LCAT gene, including 
0.851 kb of the 5 ′ fl anking region and 1.134 kb of the 3 ′ 
fl anking region on a C57Bl/6 background ( 6 ). The gen-
erated mice contained 15–120 copies of the transgene 
with an LCAT mass of 11–109   g/ml and   -LCAT activity 
of 607–3513 nmol/ml/h. For comparison,   -LCAT activ-
ity in control mice was only 32 nmol/ml/h. Interestingly, 
the endogenous plasma LCAT activity was increased only 
1.5- to 2-fold in the transgenic mice, indicating that in 
vivo other factors may limit full activation of the human 
enzyme in mice. 
 Francone et al. generated transgenic mice expressing 
the human LCAT gene, under control of either the natu-
ral or the mouse albumin enhancer and promoter in the 
FVB background ( 7 ).   -LCAT activity was   27.6 nmol/
ml/h in the transgenic mice expressing human choles-
terol ester transfer protein (CETP) under control of the 
natural promoter and   33.7 nmol/ml/h under control of 
the mouse albumin enhancer and promoter, compared 
with 23.0 nmol/ml/h in nontransgenic controls. Coex-
pression of human apoAI or human apoAI and apoAII in-
creased LCAT activity further. 
 TABLE 3. Effects of LCAT overexpression on atherosclerosis susceptibility in mice and rabbits 
Study Animal Model Background Diet Weeks HDL-C Non-HDL-C Atherosclerosis
( 118 )
Vaisman mouse, 100 copies
C57Bl/6
15% fat, 1.25% cholesterol, 
 0.5% cholic acid 16
 ↑ = 180%  ↑ 
Vaisman mouse, 240 copies  ↑ ↑ = 350%  ↑ 
 (120) Francone mouse C57Bl/6 15% calories from palm oil, 
 1.0% cholesterol, 0.5% 
 cholic acid
24 = = = (based on 
 analysis of 
 cholesterol 
 content of the 
 aorta)
( 119 ) Francone mouse FVB 20% fat, 1.25% cholesterol, 
 0.5% cholic acid
16  ↑ (ns)  ↑ (ns) 250% ↑ (ns)
FVB/apoAI KO  ↓ (ns)  ↑ (ns) 250%  ↑ 
( 121 ) Mehlum mouse, 30 copies C57Bl/6 11.5% fat, 1.25% cholesterol, 
 0.5% cholate
12  ↑ ↑ = 118%  ↑ (ns)
17 318%  ↑ 
22 114%  ↑ (ns)
( 122 ) Mehlum mouse, 60 copies C57Bl/6 30% fat, 5% cholesterol, 
 2% cholate
16  ↑ ↑  ↑ =
( 12 ) Rabbit NZW 0.3% cholesterol (120g) 17  ↑ ↑  ↓ 700%  ↑ 
( 137 ) Rabbit WHHL (LDLr KO) Chow 88  ↑ = =
LDLr, LDL receptor knockout; NZW, New Zealand white rabbit; WHHL, Watanabe heritable hyperlipidemic rabbit.
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uptake of cholesterol esters from the LCAT-Tg HDL was 
impaired. The observed increase in atherosclerotic lesion 
development in the Vaisman human LCAT transgenic 
mice was thus, at least in part, the result of an impaired 
SR-BI-mediated uptake by the liver, similar to that previ-
ously shown for SR-BI knockout mice ( 124 ). In humans, 
CETP offers an alternate route for delivery of HDL choles-
terol esters to the liver after transfer to apoB-containing 
lipoproteins ( 125 ). Cross-breeding of the LCAT transgenic 
mice with simian CETP transgenic mice ( 126 ) reduced to-
tal cholesterol and HDL cholesterol levels both on the 
chow diet and on the atherogenic diet ( 123 ). The levels, 
however, remained signifi cantly higher compared with 
control animals. Furthermore, expression of CETP nor-
malized the plasma clearance of cholesterol esters from 
LCAT-Tg HDL ( 123 ), as previously shown upon expres-
sion of CETP in SR-BI knockout mice ( 127, 128 ). Impor-
tantly, atherosclerotic lesion size was reduced by 41% 
upon expression of CETP in the human LCAT transgenic 
mice ( 123 ). However, in CETP/LCAT double transgenic 
animals, lesions were still   1.9-fold bigger compared with 
lesions in control and single CETP transgenic animals, in-
dicating that in the presence of CETP, high expression 
levels of human LCAT remained proatherogenic in mice. 
 A major drawback of all the studies described above is 
that they were not performed in mouse models susceptible 
to lesion development, such as the LDL receptor knock-
out or apoE knockout mouse, and that a cholate-contain-
ing atherogenic diet had to be used for long periods to 
induce some degree of lesion development. Under these 
conditions, only the effects on the formation of small, ini-
tial foam cell lesions can be determined, a condition that 
is not very relevant for the human situation. Furthermore, 
it has to be taken into account that cholate-containing di-
ets can have detrimental effects on liver function. For ex-
ample, in the study of Berti and colleagues using the 
Francone human LCAT transgenic mice, it was clearly 
stated that 19% of the mice died during the 16-week diet-
feeding period and that at the end of the study, all mice 
showed signals of hepatic steatosis and had gall bladders 
full of gallstones ( 119 ). 
 LCAT and atherosclerosis in LCAT knockout 
mouse models 
 In 1997, two independent groups published results on a 
mouse model for human LCAT defi ciency generated by 
targeted disruption of the LCAT gene in mouse embry-
onic stem cells ( 9, 10 ). Sakai and colleagues generated an 
LCAT knockout mouse in which the disrupted LCAT al-
lele lacked exons 2–5 ( 9 ), and Ng and colleagues gener-
ated a mouse lacking exon 1 ( 10 ). In both cases, the 
homozygous LCAT knockout mice had no detectable   -
HDL activity, and activity in heterozygous mice was re-
duced to 30–55% of control. In contrast to human FLD 
patients, there was no evidence of corneal opacities or re-
nal insuffi ciency in homozygous LCAT knockout mice at 
the age of 2–3 months. On chow diet, the plasma concen-
trations of total cholesterol and HDL cholesterol of the 
LCAT knockout mice were reduced to approximately 24% 
atherogenic diet that contained 20% fat, 1.25% choles-
terol, and 0.5% cholic acid for 16 weeks resulted only in 
1.2-fold higher total plasma cholesterol, HDL cholesterol, 
non-HDL cholesterol, and triglyceride levels. No informa-
tion was provided on LCAT activity in these animals ( 119 ). 
Furbee and Parks backcrossed the Francone mice to the 
C57Bl/6 background and fed them with a cholic acid-con-
taining atherogenic diet (15% of calories from palm oil, 
1.0% cholesterol, and 0.5% cholic acid) for 24 weeks 
( 120 ).   -LCAT activity was 9-fold higher in transgenics 
compared with controls (1,552 versus 166 nmol/ml/h). 
Triglyceride levels were 2-fold lower in the LCAT trans-
genics, whereas total plasma cholesterol levels were signifi -
cantly increased (1.15%). FPLC analysis, however, did not 
show signifi cant differences in the amounts of cholesterol 
transported by apoB lipoproteins or HDL ( 120 ). When 
the Mehlum LCAT transgenics were fed an atherogenic 
diet containing 11.5% fat, 1.25% cholesterol, and 0.5% 
cholic acid for 12 weeks, total cholesterol levels were 1.2-
fold higher, and HDL cholesterol was induced 2-fold 
( 121 ). In contrast to the fi ndings on chow, no effect on 
serum triglycerides was found on the atherogenic diet. Of 
note,   -LCAT activity was 1,380 nmol/ml/h under these 
dietary conditions, which was substantially lower than on 
chow diet. After 16 weeks of atherogenic diet feeding, the 
Vaisman LCAT transgenics developed 1.8-fold and 3.5-fold 
larger atherosclerotic lesions in the animals with 100 and 
240 copies of the human transgene, respectively ( 118 ). As 
mice are naturally resistant to atherosclerosis, the average 
lesion size in the animals was small, with a maximum le-
sion size of   25,000   m 2 in the human LCAT transgenic 
mice with 240 copies of the transgene. In the Francone 
mice ob the FVB background, a   2.5-fold nonsignifi cant 
increase in lesion size was observed ( 119 ). In the presence 
of human apoAI, however, a signifi cant 3.4-fold increase 
in lesion size was found. Furbee and Parks found similar 
amounts of cholesterol in aortas of Francone LCAT trans-
genic mice on the C57Bl/6 background after 24 weeks of 
atherogenic feeding, indicating that overexpression of hu-
man LCAT had no effect on atherosclerosis in this mouse 
model ( 120 ). The Mehlum human LCAT transgenics 
showed a 3.2-fold increase in lesion size after 17 weeks of 
atherogenic diet feeding but not after 12 or 22 weeks 
( 121 ). In homozygous human LCAT transgenic mice ex-
pressing 60 copies of the transgene, Mehlum and col-
leagues could not demonstrate an effect of human LCAT 
expression on lesion development ( 122 ). Importantly, 
LCAT overexpression did not protect against atheroscle-
rosis, and in the mice produced by Vaisman and col-
leagues, it even led to increased atherosclerosis in absence 
of effects on apoB-containing lipoproteins. The abnor-
mally large apoE-rich HDL particles that accumulated in 
the transgenic animals (LCAT-Tg HDL) of Vaisman and 
colleagues had a normal effl ux capacity but displayed a 
signifi cantly reduced ability to transfer cholesterol esters 
to the liver ( 118 ). Interestingly, adenovirus-mediated over-
expression of SR-BI failed to normalize the plasma clear-
ance and liver uptake of LCAT-Tg HDL cholesterol esters 
( 123 ), indicating that the ability of SR-BI to facilitate the 
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pronounced effect on early lesions compared with ad-
vanced lesions. This should, however, be confi rmed in ex-
periments in which lesion development is followed in time 
in the same animal model. In all cases, lesion size reduc-
tion coincided with a signifi cant decrease in the proathero-
genic apoB-containing lipoproteins. 
 When Ng and colleagues cross-bred their LCAT knock-
out mice to the apoE-defi cient background, a 52% reduc-
tion in atherosclerosis was also found at 8–9 months of age 
when fed regular chow diet ( 131 ). Total cholesterol was 
1.3-fold lower in these animals due to markedly decreased 
HDL cholesterol and 23% lower IDL/LDL cholesterol. 
VLDL, which transports the majority of cholesterol in 
these animals, was not affected. Interestingly, the LCAT/
ApoE double-knockout mice displayed decreased markers 
of oxidative stress, and the LDL was less susceptible to oxi-
dation, probably as a result of redistribution of paraoxa-
nase 1 from HDL to the abnormal LDL that accumulates 
in LCAT-defi cient animals. However, when Furbee et al. 
cross-bred the same LCAT knockout mice to the apoE and 
LDL receptor knockout background and induced lesion 
development with a mild atherogenic diet, which con-
tained 0.1% cholesterol and 10% calories from palm oil, a 
signifi cant increase in aortic cholesterol accumulation was 
found, indicative of enhanced lesion development ( 132 ). 
Furthermore, Lee et al. found a 3-fold increase in athero-
sclerotic lesion development upon deletion of LCAT in 
LDL receptor knockout mice that were challenged with a 
diet containing transmonounsaturated fatty acid-enriched 
fat (10% of energy) and 0.18% cholesterol for a period of 
20 weeks ( 133 ). These fi ndings by Furbee ( 132 ) and Lee 
et al. ( 133 ) are opposite to those observed in the studies of 
Lambert et al. ( 129 ) and Ng et al. ( 131 ). A possible expla-
nation for the discrepancy among the studies are the dif-
ferences in the plasma lipid responses with decreased 
apoB lipoproteins in the Lambert ( 129 ) and Ng ( 131 ) 
studies, and the increased or unchanged apoB lipoprotein 
concentrations in the studies of Furbee ( 132 ) and Lee 
et al. ( 133 ). In general, it can be concluded that the effect 
of LCAT deletion in mice on atherosclerotic lesion 
development correlates more closely with its effects on 
and 30%, and 7% and 8.4% in the mice generated by Sakai 
and Ng, respectively. Plasma apoAI levels were also re-
duced to 13% and 19%, respectively. Sakai found that trig-
lycerides were increased in males but not in females ( 9 ). 
Ng also found increased triglyceride levels, but this failed 
to reach statistical signifi cance (mouse gender unknown) 
( 10 ). The size and levels of the   -HDL were signifi cantly 
reduced in the LCAT knockout mice, whereas pre  -HDL 
was increased. LCAT knockout mice of Sakai et al. that 
were fed an atherogenic diet containing 15% fat, 1.25% 
cholesterol, and 0.5% cholic acid displayed not only nearly 
absent HDL levels but also remarkably lower plasma levels 
of proatherogenic apoB-containing lipoproteins, probably 
through upregulation of the LDL receptor and an increase 
in plasma apoE ( 9, 129 ). In addition, some mice accumu-
lated lipoprotein X (Lp-X), an abnormal lipoprotein par-
ticle within the LDL density region that is rich in free 
cholesterol and phospholipids ( 130 ). This particle also ac-
cumulates in cholic liver disease and has been shown to 
have anti-oxidant properties ( 130 ). The subset of LCAT 
knockout mice that accumulated lipoprotein X also devel-
oped proteinuria and glomerulosclerosis characterized by 
mesangial cell proliferation, sclerosis, lipid accumulation, 
and deposition of electron dense material throughout the 
glomeruli on the atherogenic diet ( 129 ). However, no oc-
ular abnormalities were found, even though corneal opac-
ities are associated with FLD and FED in humans. 
 Despite the largely decreased HDL cholesterol levels, 
atherosclerotic lesions were 85% smaller after 16 weeks of 
feeding the cholate-containing atherogenic diet ( Table 4 ). 
 Using the same diet, 99% smaller lesions were observed in 
the CETP transgenic background, whereas on the LDL re-
ceptor knockout background, 35% smaller lesions were 
observed ( 129 ). ApoE knockout mice lacking LCAT dis-
played 51% smaller lesions when fed regular chow. Inter-
estingly, in the mice with the smallest lesions (C57Bl/6 
and CETP-Tg mice), the largest reduction in lesion size 
was seen upon deletion of LCAT (  85 to   99%), whereas 
the smallest effect was seen in mice with the largest lesions 
(  35% in LDL receptor knockout). Taken together, these 
fi ndings might suggest that LCAT deletion has a more 
 TABLE 4. Effects of LCAT defi ciency on atherosclerosis susceptibility in mice 
Study Mouse Background Diet Weeks HDL-C Non-HDL-C Atherosclerosis
( 129 ) Exon 2-5 deletion
C57Bl/6
15% fat, 1.25% cholesterol, 
 0.5% cholic acid 16
 ↓  ↓ 85%  ↓ 
CETP Tg  ↓  ↓ 99%  ↓ 
LDLr KO  ↓  ↓ 35%  ↓ 
ApoE KO Chow 24–28  ↓  ↓ 51%  ↓ 
( 131 ) Exon 1 deletion ApoE KO Chow 32–36  ↓  ↓ 52%  ↓ 
( 132 ) Exon 1 deletion LDLr KO 0.1% cholesterol, 10% 
 calories from palm oil
16  ↓ = 200%  ↑ (based on analysis 
 of cholesterol content 
 of the aorta)
ApoE KO  ↓  ↑ 140%  ↑ (based on analysis 
 of cholesterol content 
 of the aorta)
( 133 ) Exon 1 deletion LDLr KO 0.18% cholesterol, 
 10% energy from
 transmonounsaturated 
 fatty acid fat
20  ↓  ↑ 284% (based on analysis 
 of cholesterol content 
 of the aorta)–312%  ↑ 
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however, be noted that the LCAT activity as well as HDL 
cholesterol levels was   5-fold lower in animals lacking the 
LDL receptor compared with controls ( 136 ). Analysis of 
atherosclerosis at 22 months of age showed that in both 
WHHL control rabbits and WHHL rabbits overexpressing 
LCAT, 84 ± 3% of the surface of the aorta was covered with 
lesions. This lack of protection despite the high HDL cho-
lesterol levels is likely due to the overwhelming presence 
of apoB-containing lipoproteins in plasma. Furthermore, 
the massive lesion coverage of the aorta indicates that the 
disease was in a very advanced stage. It might be that dif-
ferent effects would have been found if the effects were 
determined at an earlier age. 
 Comparison between mouse and rabbit studies 
 The results of the rabbit studies differ signifi cantly from 
the results shown in the mouse studies. Although most of 
the mouse studies suggest a unanticipated proatherogenic 
role for LCAT in the development of atherosclerosis, the 
rabbit studies largely confi rm an antiatherogenic role for 
LCAT. In both models, it appears that the infl uence of 
LCAT on atherosclerosis mostly depends on its effects on 
proatherogenic apoB-containing lipoproteins and to a 
lesser extent, if any, on its effects on HDL levels. In addi-
tion, the effects found are highly dependent on the pres-
ence of additional key proteins involved in RCT, such as 
CETP and the LDL receptor. Of note, viral overexpression 
of LCAT in nonhuman primates also resulted in an 
antiatherogenic profi le characterized by increased HDL 
cholesterol and decreased levels of apoB-containing lipo-
proteins ( 13 ), similar to that observed in the transgenic 
rabbits. As rabbits and nonhuman primates more closely 
resemble humans in their lipoprotein metabolism, this 
might support the theory that raising LCAT functionality 
might be benefi cial for atherosclerosis. 
 THERAPEUTIC REGULATION OF LCAT 
 Therapeutic upregulation of LCAT function has gained 
interest in the recent years, not only as enzyme replace-
ment therapy for LCAT defi ciency syndromes but also as a 
potential new therapeutic strategy for reducing athero-
sclerosis. Strategies for therapeutically raising LCAT activ-
ity include recombinant LCAT protein administration, 
viral expression of LCAT, and small-molecule activators of 
LCAT. Intravenous infusion of recombinant LCAT in 
LCAT knockout mice with or without expression of hu-
man apoAI rapidly raised HDL cholesterol and restored 
other lipid abnormalities ( 38 ). Moreover, a preliminary 
report indicated that subcutaneous injection of recombi-
nant LCAT stimulated RCT and attenuated atherosclero-
sis progression in New Zealand White rabbits ( 138 ). 
Importantly, a phase 1 clinical trial was announced re-
cently in which the effects of intravenous recombinant hu-
man LCAT infusion (ACP-501) in subjects with coronary 
artery disease will be evaluated ( 139 ). 
 Van Craeyveld et al. investigated the effects of adenoviral 
LCAT overexpression in liver on established complex fi bo-
ratheromatous atherosclerotic lesions induced by feeding 
proatherogenic apoB-containing lipoproteins than with its 
HDL-lowering effects. 
 LCAT and atherosclerosis in rabbit models 
 Unlike mice, rabbits express CETP and can develop 
spontaneous atherosclerosis. Therefore, rabbits are often 
thought to be a better model for studying atherosclerosis 
than mice. In 1996, Hoeg et al. described the generation 
of transgenic New Zealand White rabbits with a 6.2 kb ge-
nomic fragment consisting of the entire human LCAT 
gene, including 0.851 kb of the 5 ′ fl anking region and 
1.134 kb of the 3 ′ fl anking region ( 12 ). The generated rab-
bits contained 38–1,436 copies of the transgene with an 
LCAT mass of 1.9–54   g/ml and   -LCAT activity of 219–
3,217 nmol/ml/h. For comparison,   -LCAT activity of the 
control rabbits was 202 nmol/ml/h. Overexpression of 
human LCAT in the rabbit led to markedly increased con-
centrations of large HDL particles containing apoE and 
reduced the concentrations of the apoB-containing VLDL 
and LDL particles ( 12 ). ApoAI pool size was increased, 
whereas the fractional catabolic rate was decreased, indi-
cating that LCAT overexpression reduces apoAI catabo-
lism ( 134 ). 
 To study the effects of human LCAT expression on ath-
erosclerosis susceptibility, the rabbits were fed a daily ra-
tion of 120 g diet containing 0.3% cholesterol for a period 
of 17 weeks ( 12 ). Plasma LCAT activity was 101 ± 11 nmol/
ml/h in controls and 1,593 ± 101 nmol/ml/h in the trans-
genic rabbits on chow. On the cholesterol diet, LCAT ac-
tivity remained more than 3-fold that of controls. Total 
cholesterol and triglyceride levels were 28% and 24% 
lower, respectively, in the transgenic rabbits compared 
with controls. The reduction in total cholesterol was the 
consequence of a 2.6-fold decrease in non-HDL choles-
terol levels, and HDL cholesterol was 5-fold higher. Quan-
tifi cation of atherosclerosis showed that aortas of the 
control group had 35 ± 7% of the surface of the aorta cov-
ered with lesions ( Table 3 ). In marked contrast, only 5 ± 
1% of the aortic surface was covered by lesions in the 
LCAT transgenic rabbits ( 12 ). Overexpression of human 
LCAT thus protects against atherosclerosis in rabbits, 
probably due to the combined effect of the marked in-
crease in HDL cholesterol and the lowering of proathero-
genic apoB-containing lipoproteins. 
 In vivo kinetic experiments confi rmed that LCAT dose-
dependently increased the catabolism of apoB-containing 
lipoproteins, which was opposite to what was seen for 
apoAI catabolism ( 135 ). To investigate the importance of 
the LDL receptor for this enhanced catabolism, the LCAT 
transgenic rabbit was cross-bred with the Watanabe heri-
table hyperlipidemic (WHHL) rabbit, which lacks func-
tional LDL receptors due to an amino acid deletion in the 
cysteine-rich ligand-binding domain of the protein ( 136, 
137 ). As expected, circulating LDL levels were markedly 
higher in rabbits lacking the LDL receptor. Interestingly, 
no lowering of LDL cholesterol was seen upon overexpres-
sion of LCAT, which might indicate that the enhanced 
catabolism of apoB-containing lipoproteins upon overex-
pression of LCAT is mediated via the LDL receptor. It must, 
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 CONCLUSION 
 Although a half a century of extensive research has 
passed since the discovery of LCAT as a key enzyme in the 
esterifi cation of cholesterol in 1962, it has not (yet) ful-
fi lled the promise as a new therapeutic target for athero-
sclerosis. Over the years, many studies have been performed 
investigating the role of LCAT in atherosclerosis in animal 
models and humans, with many confl icting data as a re-
sult. From the animal studies, it can be concluded that the 
effects of LCAT on lipoprotein metabolism and athero-
sclerosis largely depend on the animal model used and the 
presence of additional proteins involved in the RCT path-
way, like CETP and the LDL receptor. Studies in rabbits, 
which more closely resemble humans in their lipoprotein 
metabolism, however, suggest that LCAT might be benefi -
cial for atherosclerosis. The antiatherogenic effects in rab-
bits are probably, at least partly, due to the combined 
effect of a marked increase in HDL cholesterol and the 
lowering of proatherogenic apoB-containing lipoproteins. 
Unfortunately, studies investigating LCAT-defi cient FED 
and FLD patients and individuals with CVD were largely 
contradictory and inconclusive. In FED and FLD patients, 
both increased and decreased signs of atherosclerosis have 
been reported. Several recent studies in CVD patients in-
dicate that LCAT might be proatherogenic in women, a 
fi nding that clearly does not support the presumed anti-
atherogenic function of LCAT. 
 All the studies performed during the last 50 years have 
made it clear that LCAT plays a role in the pathogenesis of 
atherosclerosis. Unfortunately, it remains unclear what 
that role is. Therefore, further investigation is required to 
establish the exact role of LCAT in the development of 
atherosclerosis. Newly developed activator(s) of endoge-
nous LCAT and recombinant LCAT infusions in humans 
will provide valuable information to establish whether tar-
geting of LCAT is a promising therapeutic strategy to re-
duce cardiovascular risk.  
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